With no cure for MS and current therapies offering little impact on the long-term outcomes of the disease, researchers at The University of Queensland have responded to the challenge by developing novel peptides for treating MS. Building on an innovative platform technology, the novel compounds are HLA subtype-specific for mutations causing particular variants of MS.

The peptides which specifically target PLP-specific CD4+T Cells enhance their tolerogenicity. Animal studies to date have shown that administration of modified peptides significantly reduces the severity and incidence of experimental autoimmune encephalomyelitis (EAE).

• Commercial partners
• Licenceⁱ